Glonghui, March 14 | Bailey Tianheng (688506.SH) was close to a 20CM rise and stop at the beginning of the session. It is now reported at 135.4 yuan, with a total market value of 54.3 billion yuan. The company announced yesterday after the market that the injectable BL-M05D1 (ADC) program for treating locally advanced solid tumors has obtained a Phase I clinical trial approval notice. In addition, a down payment of 800 million US dollars from BMS was recently received, and the FIC variety is expected to fulfill its global value.
A股异动 | 百利天恒盘初逼近20CM涨停 新药获得I期临床试验批准通知书
A-share changes | Bailitian Hengpan initially approaches 20CM rise and stop the new drug to obtain approval notice for phase I clinical trials
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.